BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 22865907)

  • 1. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
    Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L
    J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
    Moura MM; Cavaco BM; Pinto AE; Leite V
    J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
    Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
    J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
    Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
    Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS proto-oncogene in medullary thyroid carcinoma.
    Moura MM; Cavaco BM; Leite V
    Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.
    Agrawal N; Jiao Y; Sausen M; Leary R; Bettegowda C; Roberts NJ; Bhan S; Ho AS; Khan Z; Bishop J; Westra WH; Wood LD; Hruban RH; Tufano RP; Robinson B; Dralle H; Toledo SP; Toledo RA; Morris LG; Ghossein RA; Fagin JA; Chan TA; Velculescu VE; Vogelstein B; Kinzler KW; Papadopoulos N; Nelkin BD; Ball DW
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E364-9. PubMed ID: 23264394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.
    Uchino S; Noguchi S; Yamashita H; Sato M; Adachi M; Yamashita H; Watanabe S; Ohshima A; Mitsuyama S; Iwashita T; Takahashi M
    Jpn J Cancer Res; 1999 Nov; 90(11):1231-7. PubMed ID: 10622534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
    Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.
    Romei C; Elisei R; Pinchera A; Ceccherini I; Molinaro E; Mancusi F; Martino E; Romeo G; Pacini F
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1619-22. PubMed ID: 8636377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
    Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
    Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.
    Simbolo M; Mian C; Barollo S; Fassan M; Mafficini A; Neves D; Scardoni M; Pennelli G; Rugge M; Pelizzo MR; Cavedon E; Fugazzola L; Scarpa A
    Virchows Arch; 2014 Jul; 465(1):73-8. PubMed ID: 24828033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.
    Rapa I; Saggiorato E; Giachino D; Palestini N; Orlandi F; Papotti M; Volante M
    J Clin Endocrinol Metab; 2011 Jul; 96(7):2146-53. PubMed ID: 21543427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of inherited genetic variants in ret proto-oncogene of Brazilian patients with apparently sporadic medullary thyroid carcinoma.
    Guerrero IM; Pessoa CH; Olmedo DB; Pontes ER; Matos LC; Tilli TM; Barcinski MA; Gimba ER
    Thyroid; 2006 Jan; 16(1):9-15. PubMed ID: 16487008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large-scale analysis of mutations in RET exon 16 in sporadic medullary thyroid carcinomas in Japan.
    Takano T; Miyauchi A; Yoshida H; Hasegawa Y; Kuma K; Amino N
    Jpn J Cancer Res; 2001 Jun; 92(6):645-8. PubMed ID: 11429053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New multiple somatic mutations in the RET proto-oncogene associated with a sporadic medullary thyroid carcinoma.
    Dvoráková S; Václavíková E; Sýkorová V; Dusková J; Vlcek P; Ryska A; Novák Z; Bendlová B
    Thyroid; 2006 Mar; 16(3):311-6. PubMed ID: 16571096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The newly detected mutations in the RET proto-oncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma.
    Jindrichova S; Kodet R; Krskova L; Vlcek P; Bendlova B
    J Mol Med (Berl); 2003 Dec; 81(12):819-23. PubMed ID: 14618242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline RET mutation carriers in Japanese patients with apparently sporadic medullary thyroid carcinoma: A single institution experience.
    Kihara M; Miyauchi A; Yoshioka K; Oda H; Nakayama A; Sasai H; Yabuta T; Masuoka H; Higashiyama T; Fukushima M; Ito Y; Kobayashi K; Miya A
    Auris Nasus Larynx; 2016 Oct; 43(5):551-5. PubMed ID: 26837867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single missense mutation in codon 918 of the RET proto-oncogene in sporadic medullary thyroid carcinomas.
    Maeda S; Namba H; Takamura N; Tanigawa K; Takahashi M; Noguchi S; Nagataki S; Kanematsu T; Yamashita S
    Endocr J; 1995 Apr; 42(2):245-50. PubMed ID: 7627269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.